Advice
Recommended for restricted use within NHS Scotland for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma.
REASONS FOR ADVICE.
Rituximab is recommended for use by oncologists or haematologists in Scotland who have expertise in treating lymphoma. It should be administered in a hospital environment where full resuscitation facilities are available.
Download detailed advice36KB (PDF)
Medicine details
- Medicine name:
- Rituximab (MabThera®)
- SMC ID:
- 33/03
- Indication:
- CD20 positive diffuse large B-cell non-Hodgkin's lymphoma
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 March 2003